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Abstract. Microarray technology has presented the scientific
community with a compelling approach that allows for
simultaneous evaluation of all cellular processes at once.
Cancer, being one of the most challenging diseases due to its
polygenic nature, presents itself as a perfect candidate for
evaluation by this approach. Several recent articles have
provided significant insight into the strengths and limitations of
microarrays. Nevertheless, there are strong indications that this
approach will provide new molecular markers that could be
used in diagnosis and prognosis of cancers (1, 2). To achieve
these goals it is essential that there is a seamless integration of
clinical and molecular biological data that allows us to
elucidate genes and pathways involved in various cancers. To
this effect we are currently evaluating gene expression profiles
in human brain, ovarian, breast and hematopoetic, lung, colo-
rectal, head and neck and biliary tract cancers. To address the
issues we have a joint team of scientists, doctors and computer
scientists from two Virginia Universities and a major healthcare
provider. The study has been divided into several focus groups
that include; Tissue Bank Clinical & Pathology Laboratory
Data, Chip Fabrication, QA/QC, Tissue Devitalization,
Database Design and Data Analysis, using multiple microarray
platforms. Currently over 300 consenting patients have been
enrolled in the study with the largest number being that of breast
cancer patients. Clinical data on each patient is being compiled
into a secure and interactive relational database and integration
of these data elements will be accomplished by a common
programming interface. This clinical database contains several
key parameters on each patient including demographic (risk
factors, nutrition, co-morbidity, familial history), histopathology
(non genetic predictors), tumor, treatment and follow-up
information. Gene expression data derived from the tissue
samples will be linked to this database, which allows us to query
the data at multiple levels. The challenge of tissue acquisition
and processing is of paramount importance to the success of
this venture. A tissue devitalization timeline protocol was
devised to ensure sample and RNA integrity. Stringent protocols
are being employed to ascertain accurate tumor homogeneity,
by serial dissection of each tumor sample at 10ÌM frozen
sections followed by histopathological evaluation. The multiple
platforms being utilized in this study include Affimetrix, Oligo-
Chips and custom-designed cDNA arrays. Selected RNA
samples will be evaluated on each platform between the groups.
Analysis steps will involve normalization and standardization
of gene expression data followed by hierarchical clustering to
determine co-regulation profiles. The aim of this conjoint effort
is to elucidate pathways and genes involved in various cancers,
resistance mechanisms, molecular markers for diagnosis and
prognosis.
The complete mechanisms of normal cell growth and survival
are as yet a mystery. Cancer is the unregulated, uncontrolled,
abnormal growth of cells, due to genetic mutations and
alterations, which lead to abnormal expression of genes that
control these processes (3-5). To unravel the putative
mechanism involved in this abnormal growth is a complex
and vast task requiring powerful tools, on multiple levels. In
the last 2 decades, and especially the last 8 years, there have
been enormous strides in the availability, versatility and
integration of new technologies and resources in the field of
molecular biology (6, 7). With the introduction of microarray
technology, the completion of the human genome project and
the emergence of the field of bioinformatics, many previous
boundaries have been eliminated and the sky has become the
limit, or has it? (8, 9). Early reports in this field have
indicated that microarray technology, and the analysis of gene
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expression this technology delivers, is capable of providing
powerful and previously unattainable prognostic information
for several types of cancer (10-13).
To this end, 2 academic institutions and 2 hospital systems,
George Mason University (GMU), Virginia Commonwealth
University (VCU), INOVA Health System and the Massy
Cancer Center (all USA), have together embarked on an
ambitious collaboration, funded by The Commonwealth
Technology Research Fund (CTRF http://www.cit.org/ctrf-
main.asp) (Strategic institutional enhancement program) to
join their considerable and complementary research strengths
in a collaborative, strategic, basic and translational research
initiative in the field of cancer genomics. (http://www.ctrf-
cagenomics.vcu.edu/)
The main aim of this project is to find the hidden
correlations between gene expression, patient
demographics, treatment regimens and outcomes, by
enrolling a significant patient base at both the Massy Cancer
Center and INOVA. One of the most exciting and
promising outcomes of this project is the assembly of a
working infrastructure between these institutions, through
which an invaluable tissue bank has been created and a live
exchange of data and technologies has been achieved. 
There are a number of complex aspects and levels to this
project, which must be finely orchestrated to ensure the
success of this endeavor and rely heavily on the ability of each
of the institutions involved to work together as a team. This
complexity begins with: 1) the enrollment of each patient and
patient consent; 2) the coordination of the tissue bank
assembly, requiring the timely collection and storage of the
samples at the time of resection. This task involves the
cooperation and acceptance of the surgical staff at each site:
3) the assembly and storage of the encoded patient and tumor
information, in compliance with privacy regulations-Health
Insurance Portability and Accountability Act (HIPAA); 4)
storage/banking of the hospital released samples at -80ÆC.
This paper will focus mainly on the roles played by GMU
and INOVA Fairfax in this enterprise, including the
collection of patient samples, the fabrication of the cDNA
chips and data analysis. In addition the essential quality
control/quality assurances (QA/QC) of the entire processes,
in conjunction with VCU are discussed.
Materials and Methods
Tissue bank/collection of samples
INOVA/Massy Cancer Center. Only residual tissue samples from
diagnostic resected specimens, which are judged by the patient's
primary and consulting physicians, including the pathologist
handling the patient's case, to not be essential for diagnosis or
pathologic staging of the patient's disease, are collected. Prior to
surgery: 1) patients are identified for inclusion in the project from
information supplied by nurse coordinators of participating
surgeons; 2) informed consent is obtained from the patients; 3)
samples from: a) brain cancer; b) ovarian cancer; c) breast cancer;
d) leukemia; e) colo-rectal cancers and liver cancers, are collected
and frozen immediately in liquid nitrogen and assigned a unique
ID number; 4) the specimens are then sent to the pathology
department and stored at -80ÆC until released by the pathologist
for expression analysis; and finally 5) a final copy of the surgical
pathology report for each specimen in obtained and entered into
the database (Figures 1 and 3). 
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Table I. Tissue bank.  
Tissue bank count
Tissue type Specimen count
Brain 31







Head and Neck 25
Table II. Quality control/quality assurance of microarrays.
Sample QA/QC Purpose
Tissue devitalization To ensure that the correct protocol for
sample collection is in place.
Sample sharing For sample comparison and platform 
comparison with the same starting 
material.
Chip QA/QC Purpose
Plate orientation To determine correct orientation of the
384 well plates on the chip.
Random sequencing To ensure the integrity of the library.
Known gene probing To ensure the integrity of the chip 
addressing of the clones.
Negative controls To investigate the signal specificity and
threshold levels for filtering on non-
expressed genes.
POPO Staining To Investigate the integrity of the 
printing, and the concentration of the 
cDNA printed. 
Reference RNA Chip to chip validation.
Yellow test Chip and labeling validation.  Error 
model for analysis protocols.
Housekeeping genes, Chip integrity, spot saturation.
Lambda concentration 
curve
GMU/VCU. The project surgical pathologist carries out the final
histological evaluation of residual tissue at the time of sectioning
of the specimens, for RNA extraction for gene expression analysis.
This procedure ensures, to the extent possible, selection of slices
that are homogeneous for either normal or neoplastic tissue.
Tissue preparation and RNA extraction. Tissue specimens ranging in
size from approximately 1 cm3 - 3.5 cm3 are sectioned frozen using
a Leica 1850 Cryostat with high profile blades (Leica
Microsystems). Initially, a 5-Ìm slice was taken, fixed and stained
with Hematoxylin and Eosin (H&E). The team pathologist then
determined the percentage of tumor present in the sample by
viewing this initial slide. The team pathologist identified the
location of any non-neoplastic tissue that is then excised from the
frozen block. Once prepared in this manner, each tumor sample is
then measured and, using an algorithm (based on size of the
sample and OCT content, VCU), a determined number (n) of 10-
Ìm sections are taken. Each set of (n) slices are placed in 10 mL of
Trizol® (Invitrogen) and stored at -80ÆC for extraction. This
process is repeated again until the tumor is either (a) exhausted or
(b) enough sample tubes have been collected to provide an
adequate amount of RNA for hybridization. 
RNA extraction. Total RNA was extracted using the Trizol®
procedure (Invitrogen) with the following modifications. The sample
(in 10 mL Trizol®) was thawed from -80ÆC for 5 minutes at room
temperature followed by the addition of 2 mL chloroform. The
sample was then centrifuged for 15 minutes and the upper phase
transferred to a new RNase/DNase-free tube. To this fresh tube an
amount of 100% isopropanol equal to the initial volume of Trizol®
was added and the mix placed at -20ÆC for 2 hours to precipitate.
After 2 hours the sample was centrifuged at 4000 g for 30 minutes
and the resulting pellet washed once with ice-cold 70% (v/v) ethanol.
The final pellet was then allowed to air dry followed by resuspension
in 40 ÌL of RNase/DNase-free water between 55ÆC and 65ÆC for 10
minutes. The solubilized RNA was then passed through an
RNAezy® (Qiagen) cleanup column and stored at -80ÆC. 
RNA amplification. Total RNA (1.5 Ìg) was amplified using the
MessageAmpì aRNA Kit (Ambion) according to the
manufacturer’s recommendations. The aRNA was quantified in a
spectrophotometer and its purity was monitored by the ratio of
absorbance (A260/A280). The aRNA quality was monitored by
electrophoresis on agarose gels. The average size of the aRNA was
evaluated with Agilent 2100 Bioanalyzer (Agilent).
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Figure 1. Patient information flowchart.
Labeling of cDNA. RNA (10Ìg) or aRNA (4Ìg) was reverse
transcribed and labeled according to The Institute for Genomic
Research (TIGR) protocol (http://www.tigr.org/tdb/microarray/
protocolsTIGR.shtml). Briefly, RNA was heated at 70ÆC for 10
minutes in a total volume of 18.5 Ìl in the presence of 6 Ìg of random
hexamer primers (3mg/ml) (Invitrogen). The reaction was cooled on
ice for 1 minute. After brief centrifugation, 6 Ìl of 5X first-strand
buffer (Invitrogen), 3 Ìl of 0.1 M DTT, 0.6 Ìl of 50X dNTPs mix
containing 25mM dATP, dCTP, dGTP, 15mM dTTP(Fisher
Scientific) and 2mM aminoallyl-dUTP (Sigma) were added. To this,
400 units of SuperScript II reverse transcriptase (Invitrogen) were
added to the reaction. The mixture was then incubated at 42ÆC
overnight. RNA was hydrolyzed and the cDNA was purified using
Microcon YM-30 (Millipore) according to the manufacturer’s
instructions. The aminoallyl-labeled cDNA was coupled with the
Cyanine3 (Cy3) and Cyanine5 (Cy5) dye esters (Amersham
Biosciences). After purification with QIAquick PCR purification kit
columns (Qiagen), the samples were dehydrated to dryness.
Due to the lack of a "normal" control, we employ a reference
RNA for each tumor made up of a mixture of 3 tumor-specific
established cell lines. This reference RNA is then used across the
entire experiment, allowing us to make comparisons across
multiple groups. Total RNA was extracted from each set of 3 cell
lines and pooled to create a reference RNA, in addition to the
Stratagene’s Quantitative PCR Human Reference Total RNA
Reference RNA, which was employed
Microarray chip production. The GMU Microarray facility
(http://www.gmu.edu/centers/genomics/resources/microarra) has
designed and produced a human cDNA 40,000 Unigene (Research
Genetics/Invitrogen) gene microarray (2 chips 22,000 genes/chip).
Array fabrication. The Human I and Human II chips were
constructed from 417 plates of the Human cDNA library (Research
Genetics). The complete list of genes with accession numbers is
available at http://www.gmu.edu/centers/genomics/keys. cDNA
inserts were amplified directly from clones in culture using
universal library primers, GF200F (5’-CTGCAAGGCGATTAA
GTTGGGTAAC) GF200R (5’-GTGAGCGGATAACAATTTCA
CACAGGAAACAGC).
Amplification products were purified using Multiscreenì PCR
plates (Millipore), then dehydrated to dryness and resuspended in
30Ìl of 3X SSC. Selected aliquots were monitored by agarose gel
electrophoresis after purification to ensure (a) presence of and
purity of PCR product (b) correct size of product. The collection of
amplified cDNAs was printed on poly-L-lysine-coated slides in a
single replicate using Gene Machines OGR-03 OmniGrid
Microarrayer with SMP3 pins (Telechem International). 
Microarray controls. Negative controls consisting of no-template PCR
amplifications were also printed on the microarrays. Blank controls
are areas that were not printed. Blanks and negative controls were
distributed in several sub-arrays to monitor the background in
different areas on the slide surface and the background uniformly.
A set of housekeeping genes was printed to monitor their behavior
and the accuracy of the normalization protocols. Lambda DNA was
also printed as positive control. Lambda RNA is spiked into each
RNA sample as an internal standard to monitor the efficiency of
labeling and as positive control of the hybridization (Table III).
Prehybridization. Arrays of spotted cDNAs were first rehydrated in
a humidity chamber, inverted over 1X SSC, for 1 minute and 30
seconds, denatured (95ÆC for 4 seconds), and finally UV cross-
linked at 650 Mj. The microarrays were then incubated at 45ÆC for
45 minutes in prehybridization buffer containing 5X SSC, 0.1%
SDS, 1% bovine serum albumin (BSA, Sigma). After a single wash
in RNase/DNase-free water, the slides were dipped once in
isopropanol and air-dried. 
Hybridization. Cy3-labeled cDNA was combined with labeled Cy5
cDNA in a total volume of 45Ìl hybridization buffer (25%
formamide, 5X SSC, 0.1% SDS) for each slide, denatured at 95ÆC
for 3 minutes and applied to a prehybridized microarray slide under
a lifterslipì (Erie Scientific). The microarray slide was incubated at
45ÆC overnight in a sealed humidified hybridization chamber (CMT-
hybridization chamber, Corning Costar). After overnight
hybridization slides were washed twice in 1X SSC, 0.2% SDS (10
minutes, 45ÆC), twice in 0.1X SSC, 0.1% SDS (10 minutes, 45ÆC),
twice in 0.1X SSC (10 minutes, 45ÆC), rinsed once in RNase/DNase-
free water, and dried by brief centrifugation (400g 1 min).
Scanning and normalization. All image acquisition was carried out
using the ScanArray Express HT confocal laser scanner with setting
at 75% of photomultiplier tube, 75% of laser power and 10 Ìm of
pixel resolution. Images were acquired by ScanArray Express 2.0
software (GSI Lumonics) and processed with Quantarray 3.0
software (Packard Bioscience). 
Quality assurance/quality control (QA/QC). To ensure accuracy in
each step of this process and to ensure each team is operating
within the same guideline, a series of QA/QC experiments were
performed. These tests are divided into two categories: Sample
QA/QC and Process QA/QC (Table II).
Tissue devitalization. To ensure that the freezing process preserved
the integrity of the samples RNA, large samples, that did not
contain necrotic tissue, were divided immediately at resection and
frozen at –80ÆC at time 0, 15, 30, 60 and 130 minutes. The RNA
from each sample was then extracted and analyzed by 260/280 OD,
gel electrophoresis and Bioanalyzerì. Each group, as they receive
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Figure 2. Database, integrative knowledge base.
samples large enough, carry out this procedure and the resulting
RNA is then shared between both GMU and VCU. This allows
both groups to compare each step of the process.
Plate orientation and known gene probing
Plate orientation. To ensure the correct orientation of each of the
384 well plates loaded on the Omnigrid Micorarrayer, random
clones and their destination addresses were selected such that no
two selected clones would lie next to each other. Plasmid DNA was
extracted from each of the selected clones and the insert DNA was
amplified by PCR. Each insert was labeled using the Megaprime Kit
(Amersham/Pharmacia) according to the manufacturer’s protocol
and using fluorescent label. The resulting labeled genes were
combined and hybridized to the chip, as previously mentioned.
Based on the known location of each of the clones on the
microarray, a specific pattern of fluorescent spot would result. If the
pattern was incorrect, it was possible to determine if the plates were
place on the array deck in the inverted orientation.
Known gene probing. Ten genes were randomly selected from the
library, the only essential criteria being that each of the clones were
contained within the same vector. Each clone was then in vitro
transcribed to RNA using MAXIscript kit (Ambion). The resulting
RNA was then labeled as previously mentioned and hybridized to H1
and H2. This technique ensures proof of accurate gene position on
the microarray and the specificity of hybridization. In addition this
step reinforces our sequencing and plate orientation experiments.
Grant et al: Microarrays in Cancer Research
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Figure 3. Clinical data model.
Random sequencing. Random clones were selected and sequenced.
The resulting sequences were compared with the known sequences
for the clones accession number and clone ID. Since it is essentially
beyond our financial resources to sequence each of our 40,000
clones, this method allows us to ensures accurate knowledge of the
genes arrayed 
Negative controls. Negative controls were included within the chip
printing process. These controls are areas on the chip where the
spots were a) PCR-negative controls; b) resuspension buffer only
(3X SSC); c) areas included in the array format that were not
printed (blanks). These negative controls test for background level
and interference of PCR product/contamination.
POPO -3 staining. POPO‘-3 (Molecular Probes) DNA staining was
performed in triplicate to monitor the number of spots that
contained PCR products and to identify genes that failed either the
PCR amplification or the printing procedure. First, the 1mM stain
was diluted 10,000 fold in 1X TE buffer and each slide was
incubated at room temperature for 4 minutes. The microarray was
then incubated for 1 minute in a primary 1X TE buffer solution and
then for 3 additional minutes in a secondary 1X TE buffer solution.
Using a swinging bucket centrifuge, the slides were spun-dry at 650g
at room temperature for 3 minutes. The microarrays were next
scanned in the Cy3 channel using ScanArray Express HT.
The intensity of a spot was considered significant if it was
recorded to be higher than the median local background plus two
standard deviations calculated in each sub-array.
Reference RNA. For each of our experiments we used Universal
Human Reference RNA, Stratagene (Cat #740000), which is
composed of RNA from 10 cell lines. This RNA was labeled as
previously mentioned for either the Cy3 channel or the Cy5
channel. This use of human reference RNA allows us to have a
non-variable internal standard in each of our experiments.
Reference RNA allows us to look at labeling efficiency over our
experiments, hybridization efficiency and slide-to-slide variability.
Yellow test/dye swap/labeling & hybridization efficiency
Yellow test. The yellow test or "self to self" test uses the same cDNA
independently labeled with Cy3 and Cy5. The cDNAs were then
combined in equal quantities and hybridized with the arrays. This
test demonstrates labeling efficiency and hybridization efficiency.
The resulting hybridization scan presents all yellow spots and the
normalized Cy5/Cy3 ratio are supposed to be equal to one. This
experiment quantifies the variability and determines the number of
false-positives in a comparison between 2 preparations of the same
cDNA population. This experiment also provides a control to set
all the parameters for the analysis (filtering threshold,
normalization protocols…) in order to reduce the number of false-
positives and to identify a "cut-off threshold" for the identification of
up- or down-regulated genes in a comparison of two different RNA
populations.
Dye swap. To investigate labeling bias an additional dye swap
experiment was carried out where first, two populations of RNA
were labeled one Cy3, one Cy5 and hybridized. Second, the dyes
(Cy3 and Cy5) were reversed and hybridized, to achieve a complete
reverse of the order. Furthermore, combining individually Cy5-
labeled cDNA with pooled Cy3-labeled cDNA, followed by dye
swap, tested variability in the labeling step due to dye batch
variation and technique.
Housekeeping genes, Lambda concentration curve. A series of 10
Lambda DNA spots were included on each array at concentrations
between 20Ìg-0.002Ìg. Lambda RNA (Panvera) was labeled as
previously mentioned and spiked into the hybridization reactions.
A set of housekeeping genes (Table III) was also included in the
printing of each chip for monitoring.
Data management and analysis. The CTRF Cancer Genomics
project generates data from a variety of diverse sources. Broadly,
the data can be characterized into three categories: clinical,
experimental and metadata. Clinical data is that derived from the
ANTICANCER RESEARCH 24: 441-448 (2004)
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Table III. Housekeeping genes.
Housekeeping genes Abbreviation 3' Accession number




Tubulin, Alpha 1 TUBA1 AA180742
Phosphofructokinase, PFKP AA608558
Mitochondrial Ribosomal MRPL19 AA521243
Protein L19
Lactate Dehydrogenase A LDHA AA497029
Angio-Associated, AAMP AA452848
Migratory Cell Protein
Actin, Beta ACTB AA031770
Ribosomal Protein S27a RPS27A AA625632
Phosphoglycerate Mutase 1 PGAM1 AA676970
Ribosomal Protein L11 RPL11 AA680244
Phosphoglycerate Kinase 1 PGK1 AA599187
Non-POU-Domain-Containing, NONO AA056465
Octamer-Binding
Rho GDP Dissociation ARHGDIA AA453756
Inhibitor (GDI) Alpha
Asparagine Synthetase ASNS AA894927
Hypoxanthine  HPRT1 N47312
Phosphoribosyltransferase 1
Rho GDP Dissociation ARHGDIA AA459400
Inhibitor (GDI) Alpha
Aldolase A, Fructose- ALDOA AA775241
Bisphosphate
Beta-2-Microglobulin B2M AA670408
Heat Shock 90kd HSPCA N62400
Protein 1, Alpha
Heat Shock 90kd HSPCA AA199881
Protein 1, Alpha
Ribosomal Protein L29 RPL29 AI018613
Ribosomal Protein S3 RPS3 AA046713
Ribosomal Protein L19 RPL19 AA707531
Phosphoglycerate Kinase 1 PGK1 AA426516
Ribosomal Protein L19 RPL19 AA983933
Rho GDP Dissociation ARHGDIA AA099160
Inhibitor (GDI) Alpha
patient, including clinical tests, pathology reports and demographic
information. The experimental data is the actual gene expression
data, derived from either two-color cDNA or one-color Affymetrix
microarray gene expression experiments. Finally, the metadata is
the data about the provenance of the experimental data, including
the sample handling and experimental protocols used. Each
category of data is handled differently, but with the ultimate goal of
combining with the other data in the analysis phase.
Clinical data is often difficult to deal with. The canonical
sources of data are typically dispersed across the hospital, and are
often in different formats (both electronic and non-electronic).
Additionally, the HIPAA regulations demand that identifying
information be scrubbed from patient data before it is used for
research purposes. Thus a major challenge of this project has been
the collation of clinical data into a single, comprehensive data ware
house structure. This has involved the creation of subsidiary
databases which hold scrubbed extracts from the original data
sources prior to the federation step, which creates a collated data
warehouse which can be used in analysis (Figure 3).
In contrast, the handling of the experimental data and the
metadata is a much more straightforward proposition, as much
prior work on how to handle this data has been done previously.
Specifically, the Minimum Information About Microarray
Experiments (MIAME) (14) standard defines the data required to
fully analyze a microarray experiment, while the Microarray and
GeneExpression Markup Language (MAGEML) (15) specification
allows for the exchange of microarray data using the eXtensible
Markup Language (XML). The MIAME standard has been
implemented in several different databases, including GeneX (16)
and BASE (17). The latter database also supports MAGEML and
has limited LIMS capability.
Our data management system thus consists of a redacted clinical
database (built using the Sybase relational database management
system) and the BASE software, which serves as the experimental
and metadata database. To help protect the integrity of these data,
the databases are treated as write-once, read-many repositories,
meaning that after the initial deposition, all data elements become
read only. When required for analysis, copies of data sets are
extracted from the repositories and distributed using the GeNet
software system. Data security is provided by firewalls and enhanced
by housing the database servers in a limited access computer facility.
Data analysis is accomplished using a suite of software tools.
Basic gene expression data analysis is done using the GeneSpring
software (Silicon Genetics). More complex analyses and analysis of
clinical data is performed using the S+ or R statistical software
packages, utilizing BioConductor (18) or custom-made scripts.
Standard data mining techniques such as clustering and classification
are also applied to the data, both using an unsupervised
methodology as well as partially supervised by the inclusion of prior
biological knowledge incorporated via agent technology (19).
Data analysis in this collaborative study is complicated by the
use of both two-color cDNA (GMU) and Affymetrix (VCU) gene
expression technology. Although there are currently no algorithms
proven to enable coordinate analysis with the two different
platforms (20), representative subsets of samples (see QA/QC) are
being processed in parallel by both institutions, using both
protocols. Thus when methods for cross-platform comparisons
become available, either through our current endeavors or other’s
investigations; the two data sets will be comparable via the
common subset.
Discussion
With any venture of this size, between two universities, two
hospital systems and an interdisciplinary team, a strong
commitment on all sides and dedication to the collaboration
is required. As a result of the CTRF Strategic institutional
enhancement program, we believe that, at this point, we
have attained the required infrastructure that will allow us
to continue down the road to eventually achieving our
ultimate aim of finding the hidden correlations between
gene expression, patient demographics, treatment regimens
and outcomes. 
We (GMU, VCU, INOVA) have amassed a diverse and
expanding tissue bank (Table I) and a detailed HIPAA
compliant patient record (Figure 1). As there are so many
important tasks to be addressed, each task has been
broken down to manageable pieces. At each site an
appointed individual was identified who was responsible
for leading each focus group (Figure 4), and inter-institute
lists allowed each of the group members to communicate
globally via the web. In addition, to keep each focus group
on track, monthly video-conferencing meetings have been
essential, giving us the opportunity to address technical
and administrative issues as they occur. 
One of the most intricate tasks has been coordinating the
collection of the samples. This involved, enlisting surgeons,
enrolling patients, assembling and completing each of the
questionnaires and gaining internal review board (IRB)
approval. These tasks have were intensified as each of these
procedures required the involvement of a large number of
people not used to working together on a regular basis i.e.
medical staff and researchers. Furthermore, collection of the
samples must take place at the time of surgery to ensure the
integrity of the samples. This is a high-tension environment
(the operating room) where the attending staff is constantly
rotating. To address this issue a full-time individual at each
site was employed, who is on call for each surgery, works in
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Figure 4. Focus groups.
close concert with surgeons and their staff to identify
individuals who may meet the studies criteria. The long-term
storage and tracking of each sample, the patient history and
follow up etc, is of paramount importance to the success of
this study. To ensure this integrity of each sample, the use of
LIMS, back-up freezers and sample sharing are essential.
As already mentioned in the data analysis section, at this
point direct comparison between both institutions, the cDNA
microarray data and the affymetrix data, is not currently directly
possible. However, research is on going to resolve this issue,
which will allow us to directly compare our gene expression
results online and move closer to achieving our goal.
With regard to the financial operation of this CTRF
award, each institution contributed 100% in matching funds,
and budget compliance on this project required annual
renewal and documentation of the matching funds. This
mechanism ensured institutional commitment toward the
endeavor and provided a mechanism to establish
infrastructure that could be used across other areas of
research. The overall impact of this approach will be assessed
by overall research productivity as determined by number of
publications and grants generated in related areas.
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